Zhonghong Pulin Medical Products Co., Ltd. (SHE:300981)
China · Delayed Price · Currency is CNY 13.12
-0.09 (-0.68%)
May 28, 2026, 3:04 PM CST
SHE:300981 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,337 | 2,365 | 2,420 | 2,068 | 1,564 | 4,901 |
Other Revenue | 8.69 | 8.69 | 37.08 | 37.59 | 8.88 | 8.76 |
| 2,346 | 2,373 | 2,457 | 2,105 | 1,573 | 4,909 | |
Revenue Growth (YoY) | -7.67% | -3.40% | 16.69% | 33.87% | -67.97% | 2.74% |
Cost of Revenue | 2,127 | 2,154 | 2,183 | 2,007 | 1,554 | 2,026 |
Gross Profit | 219.29 | 219.4 | 273.83 | 98.31 | 18.85 | 2,883 |
Selling, General & Admin | 247.79 | 253.26 | 242.37 | 219.06 | 133.55 | 116.2 |
Research & Development | 51.49 | 51.08 | 49.7 | 31.61 | 8.83 | 21.79 |
Other Operating Expenses | 22.62 | 22.07 | 14.86 | 18.42 | 18.66 | 52.96 |
Operating Expenses | 333.69 | 339.66 | 311.65 | 272.5 | 164.53 | 189.78 |
Operating Income | -114.4 | -120.26 | -37.82 | -174.19 | -145.67 | 2,693 |
Interest Expense | -34.89 | -31.03 | -24.09 | -15.35 | -1.66 | -1.61 |
Interest & Investment Income | 73.88 | 71.99 | 78.87 | 67.47 | 42.94 | 39.56 |
Currency Exchange Gain (Loss) | -25.22 | -25.22 | 30.07 | 9.57 | 35.72 | -23.98 |
Other Non Operating Income (Expenses) | -22.42 | -2.16 | -2.12 | -6.01 | -4.45 | -2.46 |
EBT Excluding Unusual Items | -123.05 | -106.69 | 44.91 | -118.52 | -73.12 | 2,705 |
Impairment of Goodwill | -65.02 | -65.02 | -145.85 | -71.89 | - | - |
Gain (Loss) on Sale of Investments | 41.57 | 42.86 | 48.11 | 60.19 | 51.46 | 61.34 |
Gain (Loss) on Sale of Assets | -0.36 | 0.73 | 0.85 | 0.87 | -0.21 | 3.18 |
Asset Writedown | -6.16 | -7.77 | -29.78 | -28.04 | -11.48 | -18.38 |
Other Unusual Items | 11.74 | 11.78 | 14.86 | 19.71 | 84.62 | 33.37 |
Pretax Income | -141.28 | -124.11 | -66.9 | -137.67 | 51.27 | 2,784 |
Income Tax Expense | -10.63 | -7.63 | 18.93 | -10 | -15.71 | 442.38 |
Earnings From Continuing Operations | -130.65 | -116.48 | -85.83 | -127.67 | 66.98 | 2,342 |
Minority Interest in Earnings | 4.28 | 4.09 | -1.3 | -3.2 | -0.07 | - |
Net Income | -126.37 | -112.38 | -87.13 | -130.87 | 66.92 | 2,342 |
Net Income to Common | -126.37 | -112.38 | -87.13 | -130.87 | 66.92 | 2,342 |
Net Income Growth | - | - | - | - | -97.14% | -12.07% |
Shares Outstanding (Basic) | 433 | 432 | 436 | 423 | 433 | 393 |
Shares Outstanding (Diluted) | 433 | 432 | 436 | 423 | 433 | 393 |
Shares Change (YoY) | -0.58% | -0.78% | 2.89% | -2.24% | 10.19% | 22.18% |
EPS (Basic) | -0.29 | -0.26 | -0.20 | -0.31 | 0.15 | 5.96 |
EPS (Diluted) | -0.29 | -0.26 | -0.20 | -0.31 | 0.15 | 5.96 |
EPS Growth | - | - | - | - | -97.41% | -28.03% |
Free Cash Flow | -131.52 | -186.89 | 76.51 | -61.46 | -100.95 | 1,384 |
Free Cash Flow Per Share | -0.30 | -0.43 | 0.18 | -0.14 | -0.23 | 3.52 |
Dividend Per Share | 0.350 | 0.350 | 0.250 | 0.455 | 0.489 | 1.748 |
Dividend Growth | 40.00% | 40.00% | -44.99% | -7.15% | -72.00% | 12.50% |
Gross Margin | 9.35% | 9.25% | 11.15% | 4.67% | 1.20% | 58.73% |
Operating Margin | -4.88% | -5.07% | -1.54% | -8.27% | -9.26% | 54.86% |
Profit Margin | -5.39% | -4.74% | -3.55% | -6.22% | 4.25% | 47.70% |
Free Cash Flow Margin | -5.61% | -7.88% | 3.11% | -2.92% | -6.42% | 28.19% |
EBITDA | 101.2 | 94.82 | 175.19 | 25.66 | -1.69 | 2,772 |
EBITDA Margin | 4.31% | 4.00% | 7.13% | 1.22% | -0.11% | 56.46% |
D&A For EBITDA | 215.6 | 215.08 | 213.01 | 199.84 | 143.98 | 78.68 |
EBIT | -114.4 | -120.26 | -37.82 | -174.19 | -145.67 | 2,693 |
EBIT Margin | -4.88% | -5.07% | -1.54% | -8.27% | -9.26% | 54.86% |
Effective Tax Rate | - | - | - | - | - | 15.89% |
Revenue as Reported | 2,346 | 2,373 | 2,457 | 2,105 | 1,573 | 4,909 |
Advertising Expenses | - | 15.73 | 12.05 | 8.78 | 4.86 | 5.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.